Estela Rodriguez, Associate Director of Community Outreach-Thoracic Oncology at Sylvester Comprehensive Cancer Center, shared a post on X highlighting her top 10 lung cancer abstracts from ASCO 2026 based on their potential clinical impact. The selected studies showcase some of the most exciting and innovative science across thoracic oncology and are expected to spark important discussions, debates, and future directions during this year’s ASCO Annual Meeting:
Title: Event-free survival with adjuvant selpercatinib in stage IB-IIIA RET fusion-positive NSCLC: Primary results of the phase 3 LIBRETTO-432 trial
Authors: Jonathan W. Goldman, Xuening Yang, Maximilian Hochmair, Lin Wu, Hye Ryun Kim, Luis G. Paz-Ares, Damian T. Rieke, Melissa L. Johnson, James Chih Hsin Yang, Masahiro Tsuboi, Benjamin Besse, Nivedita Sharma, Patricia H. Maeda, Patrick Peterson, Bente Frimodt-Moller, Yi Yang, Alexander E. Drilon, Yi-Long Wu
Read The Full Abstract
Title: Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non-small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trial
Authors: Chen Zhiwei, Fang Yang, Yongzhong Luo, Longhua Sun, Lin Wu, Zhengxiang Han, Yun Fan, Yanqiu Zhao, XingYa Li, Haipeng Xu, Xiangjiao Meng, Ying Liu, Zhiye Zhang, Hui Luo, Qin Shi, Xuelei Ma, Xuezhen Ma, Zhongmin Zhang, Michelle Y. Xia, Shun Lu
Read The Full Abstract
Title: Neoadjuvant lorlatinib in stage III NSCLC harboring ALK fusion: A phase 2 multicenter study (LORIN)
Authors: Chao Zhang, Yan Hu, Ben-Yuan Jiang, Lixu Yan, Si-Ying Ren, Jing-Hua Chen, Qing Zhou, Dan-Qing Li, Wenliang Liu, Yi-Long Wu, Wen-Zhao Zhong, Meng-Min Wang, Ze-Li Li
Read The Full Abstract
Title: Osimertinib with/without chemotherapy in patients with persistent ctDNA EGFR mutant (EGFRm) NSCLC at 3 weeks after 1L osimertinib: A randomized phase II study (FLAME study)
Authors: : Zhijie Wang, Jia Zhong, Jianchun Duan, Jie Zhao, Zhehai Wang, Minglei Zhuo, Chengzhi Zhou, Zhenbin Li, Xiangjun Yi, Jianhua Chang, Shi Jin, Di Wu, Qibin Song, Xiaorong Dong, Lixia Ma, Bo Jin, Dongqing Lv, Zhe Liu, Lifeng Wang, Jie Wang
Read The Full Abstract
Title: Overall survival of first-line amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Updated results from the CHRYSALIS-2 study
Authros: Joel W. Neal, Byoung Chul Cho, Yongsheng Wang, Lin Wu, Enriqueta Felip, Jiuwei Cui, Alexander I. Spira, Melina E. Marmarelis, Eiki Ichihara, Se-Hoon Lee, James Chih Hsin Yang, Sebastian Y. Michels, Joshua C. Curtin, Xuesong Lu, Zacharias Anastasiou, Isabelle Leconte, Leonardo Trani, Sujay Shah, Pascale Tomasini
Read The Full Abstract
Title: Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PD-L1–positive advanced non-small cell lung cancer (NSCLC): Results from the randomized phase 3 OptiTROP-Lung05 study
Authors: Caicun Zhou, Anwen Xiong, Wenxiu Yao, Wei Zheng, Yan Yu, Peng Chen, Hua Zhong, Hui Wang, Bolin Chen, Haiyong Wang, Yun Fan, Yunpeng Yang, Xingxiang Pu, Qiming Wang, Xia Song, Zhangzhou Huang, Xiao-bo Du, Yan Qing, Xiaoping Jin, Junyou Ge
Read The Full Abstract
Title: Tremelimumab (T) + durvalumab (D) + chemotherapy (CT) vs pembrolizumab (P) + CT in 1L non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11, KEAP1, and/or KRAS mutations (mut): Interim analysis (IA) of the phase 2b TRITON study
Authors: Ferdinandos Skoulidis, Hossein Borghaei, Edward B. Garon, Ticiana Leal, Jacob Kaufman, Stephen V. Liu, Eric S. Nadler, Sandip Pravin Patel, Solange Peters, Biagio Ricciuti, Tarek Mekhail, Ajeet Gajra, Eric C. McGary, Vu Phan, James Stevenson, Richard Lynen, Ugochinyere Emeribe, Aida Myftiu, Ashish Gautam, John V. Heymach
Read The Full Abstract
Title: Prophylactic peptide vaccine targeting resistance mutations in advanced ALK-positive lung cancer: Primary analysis from the ARCHER trial
Authors: Michael R. Conroy, Yuxuan Wang, Bert Vogelstein, Joseph C. Murray, Kristen A. Marrone, Susan C. Scott, Josephine L. Feliciano, Christine L. Hann, Christopher Thoburn, Aliyah Pabani, Patrick M. Forde, Chen Hu, Neeha Zaidi, Julie Nauroth, Julie R. Brahmer, Valsamo Anagnostou, Benjamin P. Levy, Kellie N. Smith, Mark Yarchoan, Vincent K. Lam
Read The Full Abstract
Title: Intracranial efficacy of tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): DeLLphi-304 phase 3 post hoc analysis
Authors: Giannis S. Mountzios, Byoung Chul Cho, Phil Lammers, Longhua Sun, Surein Arulananda, Fiona H. Blackhall, Tatsuya Yoshida, Myung-Ju Ahn, Salman R. Punekar, Bo Zhu, Tudor-Eliade Ciuleanu, Julien Mazieres, Antonio Lugini, Pedro Rocha, Ippokratis Korantzis, Martin Schuler, Wei Shi, Ali Hamidi, Diana Gauto, Charles M. Rudin
Read The Full Abstract
Title: Randomized phase III study of nivolumab after surgery and adjuvant chemotherapy in NSCLC (ECOG-ACRIN EA5142, ALCHEMIST)
Authors: Jamie E. Chaft, Zhuoxin Sun, Charles M. Rudin, Charles B. Simone II, Kurt R. Oettel, David E. Kozono, Ramaswamy Govindan, Jacob Sands, John V. Heymach, Luis E. Raez, Shakun M. Malik, Tom Stinchcombe, Sumithra J. Mandrekar, David E. Gerber, Jeffrey D. Bradley, Everett E. Vokes, David R. Gandara, Charles A. Staley, Suresh S. Ramalingam, Onkar Khullar
Read The Full Abstract
Other articles about Lung Cancer on OncoDaily.
